Replies to post #767095 on NorthWest Biotherapeutics Inc (NWBO)

[exwannabe]

Summary Timeline for CAR-T Transition (2017–2019):
2017: Initial EMA approval for CAR-T (Kymriah and Yescarta).

2017–2018: IFR pathway access for individual patients.

Late 2018–Early 2019: NICE cost-effectiveness evaluations and discussions.

July 2019: NICE approval and transition to routine NHS funding for specific indications (DLBCL and ALL).

2019 onwards: Full NHS commissioning and availability.

Despite being an AI quote, that all looks right.

I agree that if MHRA approved, -L will get NHS reimbursement. But will be a year or so after NWBO gets around to submitting the evidence (which is the pricing model for how they argue the price / benefit is acceptable).